A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.
作者信息
Chien Kelly S, Rodriguez-Sevilla Juan Jose, Alvarado Yesid, Montalban-Bravo Guillermo, Hammond Danielle E, Swaminathan Mahesh, Bazinet Alexandre, Kimberley Jacqueline, Bodden Kristy, Schneider Heather, Dong Xiao Qin, Pierce Sherry A, Huang Xuelin, Jabbour Elias J, Kantarjian Hagop M, Garcia-Manero Guillermo
机构信息
The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA.
出版信息
Leuk Res. 2024 Dec;147:107602. doi: 10.1016/j.leukres.2024.107602. Epub 2024 Oct 22.
Abstract
摘要
Zotero 插件